Nasus Pharma Strengthens Leadership Team With Appointment Of Eyal Rubin As EVP And CFO To Advance Intranasal Therapeutics Pipeline

Nasus Pharma announced the appointment of Eyal Rubin as its new Executive Vice President and Chief Financial Officer. Mr. Rubin joins the company with more than twenty years of financial and operational leadership experience within the global biotechnology and pharmaceutical sectors.

In his new role, Mr. Rubin will oversee Nasus Pharma’s financial management functions, including financial planning, capital allocation, funding strategy, and investor relations. His leadership is expected to support the company as it progresses its portfolio of intranasal therapeutic candidates through key clinical development and commercialization phases.

According to CEO Dan Teleman and Executive Chairman Udi Gilboa, Mr. Rubin’s extensive background in both clinical-stage and commercial-stage companies makes him a strong addition to the executive team as the company enters a period of accelerated growth. His capital markets expertise and strategic financial execution are expected to strengthen Nasus Pharma’s operational and financial framework.

Mr. Rubin previously served in senior financial roles at Protalix BioTherapeutics, BrainStorm Cell Therapeutics, and Teva Pharmaceutical Industries. He noted that he is excited to join Nasus Pharma at a pivotal moment and believes the company’s intranasal drug delivery platform provides an opportunity to address high unmet medical needs and contribute to long-term growth.